Surrozen doses first DUET patient, expands Phase 2a to 150 patients in DME studyNov 9Quarterly updateSurrozen, Inc./DE
Surrozen closes $95.1 million second tranche after FDA IND clearance for SZN-8141Oct 20Quarterly updateSurrozen, Inc./DE
Surrozen reports Q2 2026 results, plans SZN-8141 IND filing by Q3 endAug 6Quarterly updateSurrozen, Inc./DE
Roche's lebrikizumab asthma trial posts results; new faricimab trial planned for eye diseaseJul 2Weekly roundup, 2 itemsfaricimablebrikizumab